It might sound somewhat controversial, but there are concrete reasons to rule out the existence of a real peak in human life. Instead, we are more about pursuing constant progression, thus giving ourselves a chance to become better under all circumstances. Some ripple effects to come out of that, of course, involve a direct upgrade within our surroundings. Now, throughout the history, we have scaled up on a personal and societal level through various methodologies, but despite the crazy volume, the world never quite encountered something as groundbreaking as technology. While technology propelling us towards an improved life was always evident, the fact that it reinvented world’s entire function in the process wasn’t quite expected. If we are to further zoom in upon the degree of the said transformation, one helpful example can be what happened across our global healthcare system. Practically ravaged by outdated approaches, the medical sector saw a complete revival when it pledged its allegiance to technology. All of a sudden, we had tremendously enhanced healthcare prospects at our disposal, which are now set to get even more valuable. This belief was backed up big time by a recent acquisition.
Sanofi has officially agreed a deal in principle to acquire immuno-oncology company, Amunix Pharmaceuticals. The deal will reportedly cost Sanofi around $1 billion up front, with additional $225 million expected to be staggered across a wide assortment of developmental milestones. To understand the motivation behind Sanofi making such a huge financial commitment, we must look into the Amunix Pharmaceuticals’ advanced take on immuno-oncology. For instance, as Sanofi described in its press release, Amunix’s lead drug candidate, AMX-818 is proven to allow conditional activation of the biologics in the disease-specific microenvironments. The particular process has, so far, resulted in significant tumor regression. Furthermore, it seemingly puts up a fight against possibilities concerning unwanted immune attack and other related complications,
“The Amunix technology platform utilizes a next generation smart biologics approach to precisely tailor-deliver medicines to become active only in tumor tissues while sparing normal tissues, thus bringing the promise of more effective and safer treatment options for cancer patients. We are excited to rapidly advance Amunix’s promising pipeline…,” said John Reed, global head of research and development, Sanofi.
Both Sanofi and Amunix have had a business relationship for some time now, and when you consider the former’s growing interest in diversifying its portfolio coupled with the latter’s new-age capabilities, the decision to take things up a notch makes total sense.
